Metformin Increases Lifespan and Delays Tumors in Mice
Author Information
Author(s): Anisimov Vladimir N., Berstein Lev M., Popovich Irina G., Zabezhinski Mark A., Egormin Peter A., Piskunova Tatiana S., Semenchenko Anna V., Tyndyk Margarita L., Yurova Maria N., Kovalenko Irina G., Poroshina Tatiana E.
Primary Institution: N.N.Petrov Research Institute of Oncology, Pesochny-2, St.Petersburg, Russia
Hypothesis
Does metformin treatment started at different ages affect lifespan and tumor development in female SHR mice?
Conclusion
Metformin treatment started early in life increases lifespan and delays tumor development in female SHR mice.
Supporting Evidence
- Metformin treatment started at 3 months increased mean lifespan by 14%.
- Treatment at 9 months increased mean lifespan by 6%.
- Treatment at 15 months did not increase lifespan.
- Metformin delayed first tumor detection by 22% and 25% when started at 3 and 9 months, respectively.
- Mean lifespan of tumor-free mice increased by 21% in the youngest group.
Takeaway
If you give mice a medicine called metformin when they are young, they live longer and get tumors later than if they don't get the medicine.
Methodology
Female SHR mice were treated with metformin starting at 3, 9, or 15 months of age, and their lifespan and tumor development were monitored.
Limitations
The study only included female SHR mice, which may limit the generalizability of the findings.
Participant Demographics
Outbred Swiss-derived female SHR mice.
Statistical Information
P-Value
0.181
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website